Results 221 to 230 of about 133,411 (313)

Evaluating inclusiveness and diversity in health misinformation correction research: A scoping review

Health Information &Libraries Journal, EarlyView.
Abstract Background The inclusion of marginalized populations in health information research is crucial for ensuring equitable health outcomes and addressing systemic disparities. However, underrepresentation of these groups remains a significant issue, particularly in health misinformation correction research.
Romy RW, Junhan Chen, Yuan Wang
wiley   +1 more source

The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis. [PDF]

PLoS Med
Goodfellow L, Procter SR, Koltai M, Waterlow NR, Filipe JAN, Wong CKH, van Leeuwen E, Eggo RM, Jit M, WHO Technical Advisory Group for the Full Value of Influenza Vaccines Assessment and project team, Next-generation influenza vaccine impact modelling contributors.   +10 more
europepmc   +1 more source

Effective communication and public engagement strategies to counter misinformation about infectious diseases

Immunology &Cell Biology, EarlyView.
Public trust and cooperation in infectious disease control rest on three pillars: engagement, vaccine communication, and data presentation. Together, these foundations support resilient and inclusive public health responses to misinformation and uncertainty.
Sheena Cruickshank, Martin McKee, Christina Pagel   +2 more
wiley   +1 more source

Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans

Immunology &Cell Biology, EarlyView.
In this study, we characterize a distinct subpopulation of undifferentiated invariant natural killer T (iNKT) cells in the peripheral blood of healthy adults, which are characterized by CD38 expression in a resting state. This CD38+ subset closely resembles iNKT cells from cord blood and thymus, exhibiting a unique cytokine profile and alterations in ...
Christopher Menne, Naeimeh Tavakolinia, Louis Perriman, Wiebke Moskorz, Christine Cosmovici, Andreas Walker, Lara Olejnik, Katharina Raba, Mei RM Du, Fernando J Rossello, Igor E Konstantinov, Stuart P Berzins, Daniel G Pellicci, Jörg Timm   +13 more
wiley   +1 more source

Development Strategies for Influenza Vaccines Utilizing Phage RNA Polymerase and Capping Enzyme NP868R. [PDF]

Chem Bio Eng
Wang W, Ma Z, Lou Q, Li T, Huang Z, Yin W, Lou C, Xiang Y.   +7 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Mass‐Standardised Differential Antibody Binding to a Spectrum of SARS‐CoV‐2 Variant Spike Proteins: Wuhan, Alpha, Beta, Gamma, Delta, Omicron BA.1, BA.4/5, BA.2.75 and BA.2.12.1 Variants—Antibody Immunity Endotypes

Immunology, EarlyView.
Fully quantitative, mass‐standardised, antibody responses to ten SARS‐CoV‐2 variants show significant variation in immunity profiles or endotypes. The incidence of the complete response to all variants is significantly improved after three vaccinations.
Philip H. James‐Pemberton, Shivali Kohli, Jordan Twynham, Aaron C. Westlake, Alex Antill, Rouslan V. Olkhov, Andrew M. Shaw   +6 more
wiley   +1 more source

Pharmacovigilance-based 12-year post-marketing safety analysis of quadrivalent influenza vaccines in children: a VAERS surveillance study. [PDF]

Front Pediatr
Fu H, Huang Y, Wang X, Zhang Y, Liu Y, Su Y, Pan L.   +6 more
europepmc   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source

Global production capacity of seasonal and pandemic influenza vaccines in 2023. [PDF]

Vaccine
Taaffe J, Goldin S, Lambach P, Sparrow E.   +3 more
europepmc   +1 more source